Evidence map›Paper›PMID 27069628›Full record

ArticlePharmacology research & perspectives2016

Deguelin-induced blockade of PI3K/protein kinase B/MAP kinase signaling in zebrafish and breast cancer cell lines is mediated by down-regulation of fibroblast growth factor receptor 4 activity.

Wei Wu, Yang Hai, Lu Chen, Rui-Jin Liu, Yu-Xiang Han, Wen-Hao Li, Song Li, Shuo Lin, Xin-Rong Wu

Open access · goldAbstract read
In one paragraph

Article in Pharmacology research & perspectives, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Wei WuDepartment of Pharmacy Guangzhou Liu Hua Qiao Hospital 111 Liuhua Road Guangzhou Guangdong 510010 China.
Yang HaiDepartment of Pharmacy Guangzhou Liu Hua Qiao Hospital 111 Liuhua Road Guangzhou Guangdong 510010 China.
Lu ChenSchool of Chemical Biology and Biotechnology Peking University Shenzhen Graduate School Shenzhen Guangdong 518055 China.
Rui-Jin LiuDepartment of Pharmacy Guangzhou Liu Hua Qiao Hospital 111 Liuhua Road Guangzhou Guangdong 510010 China.
Yu-Xiang HanSchool of Chemical Biology and Biotechnology Peking University Shenzhen Graduate School Shenzhen Guangdong 518055 China.
Wen-Hao LiDepartment of Pharmacy Guangzhou Liu Hua Qiao Hospital 111 Liuhua Road Guangzhou Guangdong 510010 China.
Song LiSchool of Chemical Biology and Biotechnology Peking University Shenzhen Graduate School Shenzhen Guangdong 518055 China.
Shuo LinSchool of Chemical Biology and Biotechnology Peking University Shenzhen Graduate School Shenzhen Guangdong 518055 China; Department of Molecular Cell and Developmental Biology University of California Los Angeles California 90095 USA.
Xin-Rong WuDepartment of Pharmacy Guangzhou Liu Hua Qiao Hospital 111 Liuhua Road Guangzhou Guangdong 510010 China.
421 Hospital of PLA · CNPeking University · CNUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deguelin, a natural component derived from leguminous plants, has been used as pesticide in some regions. Accumulating evidence show that deguelin has promising chemopreventive and therapeutic activities against cancer cells. This study shows that low concentrations of deguelin can lead to significant delay in zebrafish embryonic development through growth inhibition and induction of apoptosis. Furthermore, we identified fibroblast growth factor receptor 4 (FGFR4) as the putative target of deguelin. The candidate was initially identified by a microarray approach and then validated through in vitro experiments using hormone-responsive (MCF-7) and nonresponsive (MDA-MB-231) human breast cancer cell lines. The results show that deguelin suppressed cell proliferation and induced apoptosis in both cancer cell lines, but not in Hs 578Bst cells, by blocking PI3K/AKT and mitogen-activated protein kinases (MAPK) signaling. The FGFR4 mRNA and protein level also diminished in a dose-dependent manner. Interestingly, we found that forced FGFR4 overexpression attenuated deguelin-induced proliferative suppression and apoptotic cell death in both zebrafish and MCF-7 cell lines, p-AKT and p-ERK levels were restored upon FGFR4 overexpression. Taken together, our results strongly suggest that deguelin inhibition of PI3K/AKT and MAPK signaling in zebrafish and breast cancer cell lines is partially mediated through down-regulation of FGFR4 activity.

Indexed as

Breast cancerdeguelinFGFR4zebrafish

Identifiers

PMID27069628
PMCPMC4804323
OpenAlexW2281957272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.